Drug intelligence / Profile preview

PF-07055087

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral (as Metabolite Formed In Vivo Following Oral Abrocitinib Administration)

Overview

PF-07055087 is an active metabolite of abrocitinib (PF-04965842), a pharmaceutical small molecule developed by Pfizer. Abrocitinib itself is a selective Janus kinase 1 (JAK1) inhibitor, used primarily for the treatment of moderate to severe atopic dermatitis. PF-07055087 is formed via biotransformation in the body following administration of abrocitinib, and has been studied for its pharmacokinetics and potential contribution to therapeutic and safety profiles. PF-07055087 is not itself being developed as a standalone drug but is relevant as a metabolite in pharmacokinetic and safety studies of abrocitinib[2].

Targets

JAK1 (Janus kinase 1)

Beyond the preview

Go deeper on PF-07055087.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07055087.

Explore the full profile